Retrospective Non-Interventional Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients With Non-Muscle-Invasive Bladder: Real-World Experience From Six Hospital Centers in Greece

Author(s)

Angelopoulos P1, Markopoulos T1, Lazarou L1, Skolarikos A1, Stamatakos P2, Papadopoulos I. G2, Fragkoulis C2, Doumas K2, Moulavasilis N3, Levis P4, Papanikolaou D5, Sokolakis I5, Chatzimouratidis K5, Tzanetakos C6, Psarra M6, Mavridoglou G7, Skriapas K8, Akrivou D8, Karagiannis D8, Noutsos C9, Georgiou A9, Hastazeris K9, Gourzoulidis G6, Mitropoulos D3
12nd Department of Urology,Sismanogleio Hospital, Athens Medical School, Athens, Greece, 2Department of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece, 31st Department of Urology, "Laiko" Gen. Hospital, University of Athens Medical School, Athens, Greece, 41st Department of Urology, "Laiko" Gen. Hospital, University of Athens Medical School, Holargos, Greece, 52nd Urology Department of Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 6Health Through Evidence, Athens, Greece, 7University of Peloponnese, Antikalamos, Kalamata, 17, Greece, 8Department of Urology General Hospital of Larissa, Larissa, Greece, 9Department of Urology General Hospital G.Hatzikosta, Ioannina, Greece

OBJECTIVES: While the clinical application of SII-ONCO- Bacillus Calmette-Guerin (BCG) for non− muscle-invasive bladder cancer (NMIBC) is well-established in Greece, there is a lack of real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life data on the effectiveness and safety of SII-ONCO-BCG in patients with intermediate and high risk NMIBC in Greece.

METHODS: From January 2016 to December 2023, medical records from six hospital centers were reviewed for adult patients with histologically confirmed stage Ta or T1 NMIBC (with or without carcinoma in situ [CIS]) who received at least one maintenance course of SII-ONCO-BCG after induction. Tumor recurrence and progression were monitored at scheduled time intervals. Primary outcomes included recurrence-free survival (RFS) and progression-free survival (PFS), while adverse events (AEs) constituted secondary outcomes.

RESULTS: A total of 162 patients receiving SII-ONCO-BCG were enrolled. Among all patients, 145 (89.5%) patients were men, 88 (54.3%) aged 70 years or older, 103 (63.6%) had T1, 43 (26.5%) Ta, and 21 (12.9%) concurrent CIS. The median follow-up duration was 28.9 months (range, 5-36) and the mean BCG intravesical instillation courses were 13.7 (range, 9-27). After 3-, 2-, and 1-year follow-up, RFS rates of 85.2% (95% CI, 79.7%-90.7%), 85.8% (80.4%-91.2%), and 87.0% (81.8%-92.3%) were observed, respectively. The corresponding 3-, 2-, and 1-year PFS rates were 96.9% (94.2%-99.6%), 96.9% (94.2%-99.6%), and 97.5% (95.1%-99.9%), respectively. During the whole follow-up period, 24 (14.8%) patients experienced at least one AE. The most frequent AEs were hematuria and dysuria, whereas all AEs were grade 1 and 2.

CONCLUSIONS: This real-world study demonstrates that SII-ONCO-BCG is an effective and safe treatment for patients with intermediate- and high-risk NMIBC in Greece.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

CO56

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Electronic Medical & Health Records

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×